Skip to Content

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

Although a head-to-head comparison is lacking, a new study presented at EHA23 suggests that acalabrutinib and zanubrutinib are likely comparable in terms of efficacy in treating R/R CLL. Listen to Alan Skarbnik, Director of the Lymphoma and CLL Program at the Novant Health Cancer Institute, North Carolina, sharing the findings of this study.

Alan Z. Skarbnik

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top